Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BiomaximaWAR:BMX +4.38%51 FCF Yield % is 1.11 as of Jul. 21, 2026, which is 1010% above its 10-year median of 0.10. GuruFocus rates WAR:BMX with a GF Score™ of 51/100 and a GF Value™ of zł15.43 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 213 Medical Diagnostics & Research companies, Biomaxima ranks better than 62.91% on this metric.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
The historical rank and industry rank for Biomaxima's FCF Yield % or its related term are showing as below:
WAR:BMX'
s FCF Yield % Range Over the Past 10 Years
Min: -99.2 Med: 0.1 Max: 27.43
Current: 1.11
During the past 13 years, the highest FCF Yield % of Biomaxima was 27.43%. The lowest was -99.20%. And the median was 0.10%.
WAR:BMX's FCF Yield % is ranked better than 62.91% of 213
companies
in the Medical Diagnostics & Research industry
Industry Median: -1.21
vs WAR:BMX: 1.11
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Biomaxima FCF Yield % Related Terms
Biomaxima FCF Yield % Historical Data
* Premium members only.
The historical data trend for Biomaxima's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Biomaxima's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biomaxima FCF Yield % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Biomaxima's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Biomaxima's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biomaxima (WAR:BMX) has a FCF Yield % of 1.11 as of Jul. 21, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Biomaxima and its competitors. This is 1010% above median its historical median of 0.10. According to the industry distribution chart, Biomaxima ranks #79 out of 213 companies in the Medical Diagnostics & Research industry, placing it in the top 37.1%.
Is Biomaxima's FCF Yield % too high?
Biomaxima's current FCF Yield % of 1.11 is 1010% above median its 10-year median of 0.10. Based on the distribution chart, Biomaxima ranks #79 out of 213 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Biomaxima has a GF Score™ of 51/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Biomaxima's FCF Yield % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Biomaxima ranks #79 out of 213 companies for FCF Yield %. This puts Biomaxima in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Medical Diagnostics & Research company?
A good FCF Yield % depends on the Medical Diagnostics & Research industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Biomaxima and its competitors. Biomaxima's current FCF Yield % is 1.11, which is 1010% above median its own 10-year median of 0.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biomaxima stock overvalued right now?
Based on GuruFocus' analysis, Biomaxima (WAR:BMX) is currently considered Possible Value Trap. The stock's GF Value™ is zł15.43, compared to a current price of zł9.77 — trading 36.7% below its estimated fair value. The current FCF Yield % is 1.11, which is 1010% above median its 10-year median of 0.10. Biomaxima's overall GF Score™ is 51/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Biomaxima (WAR:BMX), the current FCF Yield % is 1.11 as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Biomaxima (WAR:BMX) Overvalued in 2026?
Based on GuruFocus' analysis, Biomaxima stock appears to be undervalued.
The current stock price of zł9.77 is trading 36.7% below its estimated GF Value™ of zł15.43.
GuruFocus considers Biomaxima to be Possible Value Trap.
Key valuation signals for WAR:BMX:
FCF Yield %: 1.11 (1010% above median its 10-year median of 0.10)
GF Value™: zł15.43 vs. price of zł9.77 (36.7% below fair value)
No single metric tells the full story. See the WAR:BMX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioMaxima SA is a Polish company operating in the market of laboratory diagnostics. It is a manufacturer of microbiological substrates as well as a wide range of reagents and diagnostic equipment. The company is also a distributor of products of recognized multinational diagnostic companies such as: Accelerate Diagnostics, Nova Biomedical, PHC Group, Technoclone, Kabe and Biolog.
51GF Score
Get the complete analysis for WAR:BMX
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WAR:BMX has been successfully added to your 
